Molecular Biology of Canine Parainfluenza Virus V Protein and Its Potential Applications in Tumor Immunotherapy

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2024 Jan 4

PMID 38173672

Authors

Huai Cheng

Hewei Zhang

Huanchang Cai

Min Liu

Shubo Wen

Jingqiang Ren

Affiliations

Soon will be listed here.

Abstract

Canine parainfluenza virus (CPIV) is a zoonotic virus that is widely distributed and is the main pathogen causing canine infectious respiratory disease (CIRD), also known as "kennel cough," in dogs. The CPIV-V protein is the only nonstructural protein of the virus and plays an important role in multiple stages of the virus life cycle by inhibiting apoptosis, altering the host cell cycle and interfering with the interferon response. In addition, studies have shown that the V protein has potential applications in the field of immunotherapy in oncolytic virus therapy or self-amplifying RNA vaccines. In this review, the biosynthesis, structural characteristics and functions of the CPIV-V protein are reviewed with an emphasis on how it facilitates viral immune escape and its potential applications in the field of immunotherapy. Therefore, this review provides a scientific basis for research into the CPIV-V protein and its potential applications.

References

Charoenkul K, Nasamran C, Janetanakit T, Chaiyawong S, Bunpapong N, Boonyapisitsopa S . Molecular detection and whole genome characterization of Canine Parainfluenza type 5 in Thailand. Sci Rep. 2021; 11(1):3866. PMC: 7887266. DOI: 10.1038/s41598-021-83323-9. View

Zamarin D, Holmgaard R, Subudhi S, Park J, Mansour M, Palese P . Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014; 6(226):226ra32. PMC: 4106918. DOI: 10.1126/scitranslmed.3008095. View

Parks G, Alexander-Miller M . Paramyxovirus activation and inhibition of innate immune responses. J Mol Biol. 2013; 425(24):4872-92. PMC: 3940258. DOI: 10.1016/j.jmb.2013.09.015. View

Lin G, PATERSON R, Richardson C, Lamb R . The V protein of the paramyxovirus SV5 interacts with damage-specific DNA binding protein. Virology. 1998; 249(1):189-200. DOI: 10.1006/viro.1998.9317. View

Peluso R, Lamb R, Choppin P . Polypeptide synthesis in simian virus 5-infected cells. J Virol. 1977; 23(1):177-87. PMC: 515813. DOI: 10.1128/JVI.23.1.177-187.1977. View

Fox C, Parks G . Parainfluenza Virus Infection Sensitizes Cancer Cells to DNA-Damaging Agents: Implications for Oncolytic Virus Therapy. J Virol. 2018; 92(7). PMC: 5972898. DOI: 10.1128/JVI.01948-17. View

Kolakofsky D . Paramyxovirus RNA synthesis, mRNA editing, and genome hexamer phase: A review. Virology. 2016; 498:94-98. DOI: 10.1016/j.virol.2016.08.018. View

Yaiw K, Miest T, Frenzke M, Timm M, Johnston P, Cattaneo R . CD20-targeted measles virus shows high oncolytic specificity in clinical samples from lymphoma patients independent of prior rituximab therapy. Gene Ther. 2010; 18(3):313-7. PMC: 3896318. DOI: 10.1038/gt.2010.150. View

Manzoni T, Lopez C . Defective (interfering) viral genomes re-explored: impact on antiviral immunity and virus persistence. Future Virol. 2018; 13(7):493-503. PMC: 6136085. DOI: 10.2217/fvl-2018-0021. View

10.

Kariko K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23(2):165-75. DOI: 10.1016/j.immuni.2005.06.008. View

11.

Motz C, Schuhmann K, Kirchhofer A, Moldt M, Witte G, Conzelmann K . Paramyxovirus V proteins disrupt the fold of the RNA sensor MDA5 to inhibit antiviral signaling. Science. 2013; 339(6120):690-3. DOI: 10.1126/science.1230949. View

12.

Pejawar S, Parks G, Alexander-Miller M . Abortive versus productive viral infection of dendritic cells with a paramyxovirus results in differential upregulation of select costimulatory molecules. J Virol. 2005; 79(12):7544-57. PMC: 1143689. DOI: 10.1128/JVI.79.12.7544-7557.2005. View

13.

Rao P, Gandham R, Subbiah M . Molecular evolution and genetic variations of V and W proteins derived by RNA editing in Avian Paramyxoviruses. Sci Rep. 2020; 10(1):9532. PMC: 7293227. DOI: 10.1038/s41598-020-66252-x. View

14.

Wansley E, Parks G . Naturally occurring substitutions in the P/V gene convert the noncytopathic paramyxovirus simian virus 5 into a virus that induces alpha/beta interferon synthesis and cell death. J Virol. 2002; 76(20):10109-21. PMC: 136585. DOI: 10.1128/jvi.76.20.10109-10121.2002. View

15.

Agarwal R, Kaye S . Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003; 3(7):502-16. DOI: 10.1038/nrc1123. View

16.

Matveeva O, Shabalina S . Prospects for Using Expression Patterns of Paramyxovirus Receptors as Biomarkers for Oncolytic Virotherapy. Cancers (Basel). 2020; 12(12). PMC: 7762160. DOI: 10.3390/cancers12123659. View

17.

Eskander R, Moore K, Monk B, Herzog T, Annunziata C, OMalley D . Overcoming the challenges of drug development in platinum-resistant ovarian cancer. Front Oncol. 2023; 13:1258228. PMC: 10616588. DOI: 10.3389/fonc.2023.1258228. View

18.

Kedarinath K, Parks G . Differential In Vitro Growth and Cell Killing of Cancer versus Benign Prostate Cells by Oncolytic Parainfluenza Virus. Pathogens. 2022; 11(5). PMC: 9147676. DOI: 10.3390/pathogens11050493. View

19.

Huang F, Wang J, Dai S, Lin Y, Sun Y, Zhang L . A recombinant oncolytic Newcastle virus expressing MIP-3α promotes systemic antitumor immunity. J Immunother Cancer. 2020; 8(2). PMC: 7410001. DOI: 10.1136/jitc-2019-000330. View

20.

Omagari K, Asamitsu K, Tanaka Y . Application of fluorescent-based technology detecting protein-protein interactions to monitor the binding of hepatitis B virus X protein to DNA-damage-binding protein 1. Biophys Physicobiol. 2021; 18:67-77. PMC: 8056151. DOI: 10.2142/biophysico.bppb-v18.008. View